Search

Displaying results 1081 - 1090 of 6831 in total
  1. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant]. … [A244225] Daridorexant works on orexin receptors OX1R and OX2R to block the binding of orexins, which are wake-promoting neuropeptides and endogenous ligands to these receptors.

  2. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Lodoxamide is marketed under the brand name Alomide by Alcon.

  3. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. … Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs.

  4. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    [A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937] … [A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment

  5. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. … Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.

  6. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.

  7. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. … [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side

  8. Indication

    Clostridium Difficile Associated Diarrhea (CDAD)

    go.drugbank.com/conditions/DBCOND0085319
    Drugs: Fidaxomicin · Vancomycin
    Synonyms: Enterocolitis due to Clostridium difficile
  9. Indication

    Metrorrhagia

    go.drugbank.com/conditions/DBCOND0001309
    Drugs: Lynestrenol
    Synonyms: Bleeding unrelated to menstrual cycle
  10. Indication

    Perennial Allergic Rhinitis (PAR)

    go.drugbank.com/conditions/DBCOND0058482
    Drugs: Azelastine · Beclomethasone dipropionate · Cetirizine · Ciclesonide · Cortisone acetate · Cromoglicic acid +12 more
    Synonyms: Allergic rhinitis due to allergen